T
Thigpen Jt
Researcher at University of Mississippi
Publications - 13
Citations - 1212
Thigpen Jt is an academic researcher from University of Mississippi. The author has contributed to research in topics: Gynecologic oncology & Piperazinedione. The author has an hindex of 9, co-authored 13 publications receiving 1170 citations.
Papers
More filters
Journal ArticleDOI
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
TL;DR: Taxol is a highly active agent in ovarian carcinoma, even in patients who are clinically resistant to platinum-based chemotherapy, and produces frequent and severe, albeit manageable, myelosuppression.
Journal ArticleDOI
A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas.
George A. Omura,Francis J. Major,John A. Blessing,T. V. Sedlacek,Thigpen Jt,William T. Creasman,Richard J. Zaino +6 more
TL;DR: Evaluated Adriamycin with and without dimethyl‐triazeno‐imid‐azole‐carboxamide in the treatment of Stage III or IV and recurrent sarcomas of the uterus and there was no survival advantage.
Journal ArticleDOI
A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
TL;DR: The combination of doxorubicin plus cyclophosphamide appears to offer a small advantage over doxorbicin alone in the management of endometrial carcinoma at the expense of more frequent and severe myelosuppression and gastrointestinal toxicity.
Journal ArticleDOI
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.
TL;DR: Cisplatin has definite activity when given at the dose and schedule that it is tested for patients with mixed mesodermal sarcomas who have not received prior chemotherapy, but has little activity in patients with leiomyosarcoma.
Journal ArticleDOI
Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.
TL;DR: Cisplatin thus appears tolerable but only minimally active when given at the dose and schedule tested to patients with endometrial carcinoma who have previously demonstrated progression of disease on chemotherapy with known activity.